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Abstract
BACKGROUND: We report the use of positron emission tomography (PET) using 18F-FDG for the diagnosis of carditis in chil-
dren with rheumatic heart disease (RHD). 
MATERIAL AND METHODS: Thirty-six children aged 6–17 years (seventeen males and nineteen females) with isolated rheu-
matic significant mitral regurgitation (MR) underwent FDG-PET scanning of the heart after fasting for 6 h within a period of 
2 years. They were divided into two groups based on Jones criteria — acute rheumatic carditis and chronic RHD. Age- and 
gender-matched twelve children who underwent whole body 18F-FDG-PET scan for routine PET scan for oncological evaluation 
was taken as controls. Nineteen patients had active carditis and 17 were chronic RHD cases. 
RESULTS: All 12 controls and all 17 cases with chronic RHD with MR showed diffuse uptake pattern. Of the 19 active cases, 14 
showed 18F-FDG uptake in the myocardium, 5 did not show any uptake. Thus the finding of no uptake pattern on 18F-FDG-PET 
scan had a sensitivity of 26% but positive predictive value of 100% for acute carditis cases. This study describes the 18F-FDG-PET 
uptake pattern in children with RHD and in 12 age-matched control subjects in the fasting state. Those with chronic RHD with 
MR showed diffuse myocardial uptake pattern similar to that of the control group. Patients with active carditis showed mixed 
results; the majority showed diffuse uptake pattern. 
CONCLUSION: In view of its poor sensitivity, 18F-FDG-PET is not recommended as a routine imaging modality for the diagnosis 
of rheumatic carditis.
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Background
Rheumatic fever is an abnormal, delayed, probably autoimmune 
reaction to group A beta hemolytic streptococcal pharyngitis invol-
ving joints, skin, brain, serous surfaces and heart valves. Rheumatic 
fever continues to be a major cardiovascular health problem in 
the developing countries [1–3]. Carditis is the only component 
of rheumatic fever that leads to permanent disability [4, 5] and 
accurate recognition of carditis has significant therapeutic and 
prognostic implication. 
The diagnosis of acute rheumatic fever is currently made using 
modified Jones criteria [6, 7]. The major criteria include carditis, 
polyarthritis, chorea, subcutaneous nodules and Erythema margi-
natum. The minor criteria include fever, arthralgia, and history of 
previous definitive RF/RHD, increased ESR, presence of CRP or 
leukocytosis and prolonged PR interval. Plus supporting of preced-
ing streptococcal infection: history of recent scarlet fever, positive 
sore throat culture for group A streptococcus, increased antistre-
ptolysin O and other streptococcal antibody titers. Diagnosis of 
rheumatic fever by modified Jones criteria — 1 major + 2 minor 
manifestations + essential evidence of recent streptococcal in-
fection or 2 major manifestations + essential evidence of recent 
streptococcal infection.
Nevertheless, there are cases where the Jones criteria are 
not satisfied and clinical consensus is equivocal [8, 9]. In such 
cases diagnosis of carditis may be problematic, as there is no 
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single diagnostic test. Moreover, Jones criteria were developed 
to diagnose first episode of acute rheumatic fever. Many other 
techniques have been used including echo, Doppler, radionuclide 
imaging, endomyocardial biopsy and serum markers but none 
of these are fully diagnostic [10–13]. No studies are available in 
literature regarding the role of positron emission tomography (PET) 
scan in rheumatic carditis. 
We hypothesized that PET may be helpful in picking up the 
inflammation early where the other modalities of investigation 
have failed. Fluorine-18-fluorodeoxyglucose (18F-FDG-PET) scan 
was performed in children (< 18 years) with acute rheumatic fever 
and carditis, and the results were compared with data in our pa-
tients with chronic RHD and with no heart disease. 
Materials and methods
Study design
Children < 18 years, presenting with acute rheumatic fever and 
carditis with at least moderate mitral regurgitation were enrolled 
in the study after informed consent of their parents. A total of 
19 such patients were included (Group I). The diagnosis of active 
carditis was made according to modified Jones criteria along with 
raised Anti-streptolysin O (ASLO) titer in 13 cases. In the remaining 
6 children clinical assessment, elevated erythrocyte sedimentation 
rate (ESR), C-reactive protein (CRP) and nodules on mitral valve 
leaflets on echocardiography pointed to active carditis. Modified 
Jones criteria could not be used in these children, as active cardi-
tis occurred over a previous RHD diagnosis where Jones criteria 
may not be applicable. A second group (Group II) consisted of 17 
children (< 18 years) who had chronic rheumatic mitral regurgita-
tion, at least moderate in severity, with no clinical or laboratory 
evidence of acute carditis. Twelve children < 18 years who had 
a normal heart and were undergoing PET scan for routine onco-
logical evaluation like lymphoma were also enrolled in the study 
as controls (Group III). Patients in New York Heart Association 
(NYHA) functional class IV were excluded, as were patients with 
associated aortic, tricuspid and pulmonary valve involvement. Pa-
tients with active carditis who were on more than 7 days on steroid 
treatment were also excluded. 
Imaging protocol
The study was done after at least 8 hours of fasting. Fasting 
blood glucose level was < 90 mg/dL in all patients. Patients were 
administered 5.2 MBq/kg (0.14 mCi/kg) body weight of 18F-FDG 
intravenously through an indwelling cannula. Images were acquired 
at 45 min after 18F-FDG injection on a dedicated PET-computed to-
mography (CT) scanner (Siemens, Biograph-2, USA). Images were 
acquired in craniocaudal direction with one bed position of 10 min 
duration. The PET images were reconstructed by iterative recon-
struction ordered subset expectation maximization (OSEM), with 
image size 128 × 128 matrix, zoom 1, and full width half maximum 
of 5 mm. Analysis and interpretation of the PET, images were done 
after displaying the images in conventional cardiac slices.
Results
The basic demographic profile of all cases is given in Table 1. 
Overall children with active RHD were younger as compared to 
those with chronic RHD. A total of 43 of 48 children showed diffuse 
uptake pattern on 18F-FDG-PET scan. This pattern was present 
in all Group II and Group III children. Of Group I (active carditis) 
14 of 19 children showed diffuse uptake similar to chronic RHD 
cases and normal controls. Five of active carditis group failed to 
show any uptake. The age of these 5 children ranged from 7 to 11 
years with mean no different than the mean of Group I children. Fig-
ure 1 shows diffuse uptake patter on 18F-FDG scan in a 12-year-old 
child with chronic RHD. Figure 2 shows absence of any uptake in 
an 11-year-old child with active rheumatic carditis.
We analyzed data to see if any of the clinical or laboratory 
parameters were associated with absence of uptake on 18F-FDG 
scanning in those with active carditis. There was no correlation of 
absent uptake with presence or absence of congestive heart failure, 
anemia, elevated ASLO titer, elevated ESR and CRP. No association 
was seen with severity of mitral regurgitation or nodules on mitral 
valve leaflets as seen on cross sectional echocardiography.
Discussion
Fluorine-18-FDG is a labeled glucose analog used as a radio-
tracer in PET. Following cellular uptake, it is metabolically trapped 
and consequently gives an image which portrays tissue glucose 
utilization. Inflammatory cell take up large amounts of glucose 
Table 1. Demographic profile of all cases
Parameters Group I  
(active  
carditis)
Group II  
(chronic  
RHD)
Group III  
(controls)
Number of cases 19 17 12
Age in years (mean)
6–12 years
> 12 years
9.63 ± 2.1
15
4
10.9 ± 2.7
10
7
9.8 ± 2.2
6
6
Gender 10 M
9 F
7 M
10 F
6 M
6 F
Congestive heart failure 3 2 0
RHD — Rheumatic Heart Disease, M — male, F — female
Figure 1. 18F-FDG-PET scan showing 18F-FDG-PET uptake pattern in 
a 12-year-old female child with chronic rheumatic heart disease and 
mitral regurgitation
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as a result of an increased metabolic rate. Indeed, inflammatory foci 
are the main cause of false positive 18F-FDG scans performed for 
malignant disease. Therefore 18F-FDG represents a primary agent 
for localizing inflammation. It has an in plane spatial resolution of 
4 to 8 mm, which provides better images compared to conventional 
single photon emission computed tomography (SPECT) [14]. PET 
is a very useful tool for diagnosing inflammation and yields positive 
results earlier than other studies. The radiation received is compa-
rable to other standard diagnostic modalities. Thus it is a safe and 
relatively less invasive modality for early diagnosis of inflammation.
PET has been used to detect inflammatory activity in certain 
cardiac diseases like Kawasaki disease, vasculitis and cardiac 
sarcoidosis [15–18]. Cardiac PET using 18F-FDG has been used 
for identification of cardiac sarcoidosis and assessment of disease 
activity. In a study by Okumura et al., 22 patients with systemic 
sarcoidosis were classified into two groups of 11 each according 
to the presence or absence of sarcoid heart disease [19]. PET 
could detect cardiac sarcoidosis at an early stage of the disease, 
in which fewer perfusion abnormalities and high inflammatory ac-
tivity are noted, before advanced myocardial impairment. Fasting 
18F-FDG-PET detected abnormalities more frequently than either 
Technetium-99m sestamibi (99mTc-MIBI) SPECT or Gallium-67 
(67Ga) Scintigraphy in patients with cardiac sarcoidosis. However, 
in this study all patients were adults and majority of them were in 
their 5th or 6th decade. Our study group includes predominantly the 
pediatrics population with age ranges between 6 and 17 years.
Since inflammation is underlying pathology in rheumatic car-
ditis, we undertook this study to see if 18F-FDG positron emission 
tomography (PET) is useful in diagnosing the rheumatic carditis. We 
also analyzed our data to see the relationship of PET findings with 
the age, sex, hemoglobin, ESR, C-reactive protein, ASLO titer, mitral 
valve nodularity on echo, etc.
There is little data on PET scan findings in children. Most stud-
ies have focused on its usefulness to detect myocardial ischemia, 
e.g. in Kawasaki disease, post operated congenital heart disease 
with coronary translocation, metabolic cardiomyopathy, etc. [20]. In 
an article by Shammas et al., myocardial uptake can vary from no 
discernible uptake to intense activity throughout the left ventricular 
myocardium in normal children [21]. Although chances of intense 
activity are remote in fasting state, it is well described [22]. In our 
study all children with no heart disease also showed diffuse myo-
cardial uptake on 18F-FDG-PET scan. 
The children with chronic RHD were no different from controls. 
However 5 of 19 children with active carditis showed no uptake, 
the reason for this finding remains unexplained. There is no data 
in literature on PET scan findings in patients with RHD, adults or 
children. We could not associate the scan results with any of the 
known variables for activity such as anemia, raised ESR or CRP or 
ASLO titer and with nodularity on mitral valve in echocardiography. 
During fetal development glucose metabolism is favored, 
whereas fatty acids are the primary energy substrate in the adult 
myocardium. Significant shifts in substrate preference occur in 
response to dietary (fasting/refeeding) and physiological (exer-
cise) stimuli. Certain pathophysiological contexts, like hypertro-
phy, hypoxia, and ischemia, drive metabolism toward a fetal-like 
state, whereas in diabetes the heart utilizes fatty acids almost 
exclusively. These metabolic alterations are accompanied by 
changes in expression of enzymes involved in fatty acids utilization 
mediated by nuclear receptors (peroxisome proliferator-activated 
receptors (PPAR) and estrogen-related receptor (ERR)) and the 
NR co-activator PGC-1 (PPAR coactivator-1). It is also known that 
with aging, the contribution of the myocardial fatty acid oxidation 
to overall myocardial substrate metabolism declines with age from 
the experiments done in mouse and rats. 
The possible reason for the uptake pattern seen in the control 
and the patients in the study group may be because of the pre-
dominant uptake of the glucose in the fasting states in children in 
contrast to the pattern in adults where the predominant fuel is fatty 
acids [23]. The absence of uptake pattern seen in some of the 
patients with active group is possibly because of the disturbance in 
the normal metabolic milieu by the inflammatory mediators in some 
of the active patients which results in the perturbation of this normal 
glucose uptake and resulting in the no uptake pattern. However, 
only 5 patients showed such pattern. This could be related to the 
spectrum of severity of the disease process which at a particular 
threshold of severity results in metabolic derangement. It is not clear 
at what age this fetal type of glucose uptake pattern becomes the 
adult type of fatty acid uptake pattern and needs further research 
and clarification.
Although we do not recommend PET scan for detection of active 
rheumatic carditis, this study has helped us to know the pattern of 
PET scan in normal children which is similar to those with chronic 
RHD. In our opinion this is the first 18F-FDG-PET study carried on 
pediatric cardiac patients with RHD, active and chronic. 
There are certain limitations in our study. Our study includes only 
small number of patients to support the role of PET scan in diag-
nosing the rheumatic carditis. All active carditis patients were on 
steroids for variable period but for less than 7 days when the study 
was undertaken, the drug was not discontinued due ethical reason. 
Conclusion
18F-FDG-PET scan showed diffuse myocardial uptake in 
children with chronic RHD with MR, this pattern was also seen in 
normal age-matched control subjects. Patients with acute rheumatic 
carditis may or may not show the normal uptake pattern. Hence 
PET scan does not provide additional diagnostic information where 
Figure 2. 18F-FDG-PET scan showing ‘no uptake’ pattern in 
an 11-year-old male child with active rheumatic carditis
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clinical consensus is certain about diagnosis of rheumatic carditis. 
Based on this study we cannot recommend 18F-FDG-PET scan 
as a routine diagnostic tool for diagnosis of acute rheumatic carditis. 
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